Laboratory Testing for HER2/neu in Breast Carcinoma: An Evolving Strategy to Predict Response to Targeted Therapy

Nils M. Diaz, MD, Interdisciplinary Oncology Program at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, Florida. Submitted July 1, 2001; accepted August 9, 2001

Cancer Control. 2001;8(5) 

In This Article

HER2/neu Status as a Predictor of Response to Targeted Therapy

In any given case, the key determinant of the utility of a test for HER2/neu is whether it is predictive of a patient's response to targeted therapy, which presently consists of trastuzumab. Review of the results using the clinical trials assay (CTA), an immunostaining procedure that employs monoclonal antibodies directed against HER2/neu, suggests that most patients with a beneficial clinical response to Herceptin had tumors with the highest levels of HER2/neu overexpression: 3+ in a 0-3+ scoring system.[4] Unless 2+ positive overexpression of HER2/ neu was confirmed by FISH assay for gene amplification, the probability of a therapeutic response was 0% in second-and third-line monotherapy. Some recent studies also suggest that FISH may be a better predictor than IHC of response to Herceptin.[17,18] Such results have contributed to proposals that FISH should serve as the front-line test for selecting patients for Herceptin therapy. In contrast, Seidman et al[19] found that IHC was as effective as FISH as a predictor of response to Herceptin. The predictive value of IHC and FISH may prove to vary according to how anti-HER/new therapy is used in monotherapy and in combination with nontargeted chemotherapeutic agents.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: